GeneDx Holdings
WGS on Nasdaq. GeneDx sells genetic tests to doctors and drug companies. Market value $1.6bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-7.43 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -39 cents a year. Above 10 is good.
Quality score: 44 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$45.46 a share, 41% above its 1-year low
Over the past year the price has ranged from $32.21 to $170.87.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: a shortfall of $101 million in the past 12 months, $14 million in the year to December 2025.
| Revenue | |||||
| Revenue | $212m | $235m | $203m | $305m | $428m |
| Operating margin | |||||
| Operating margin | -210.3% | -284.5% | -89.2% | -7.6% | -3.1% |
| Debt to equity | |||||
| Debt to equity | 0.03 | 0.12 | 0.33 | 0.30 | 0.23 |
| Shares outstanding | |||||
| Shares outstanding | 0.39bn | 0.03bn | 0.03bn | 0.03bn | 0.03bn |
Health checks
- Free cash flow positive1 of 5 years
- Accounting looks honest (Beneish)Nothing unusual
- Financial strength (Piotroski)5 of 9
- Profit backed by cash (accruals)No
- Debt0.23× equity
- Revenue growth, five yearsStrong, 19.1% a year
- Buying back its own sharesYes, 92% fewer since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $123 million last quarter, up 5% on a year ago.
- A loss of $12 million, compared with a loss of $8 million a year ago.
- It loses 22 cents on each $1 of sales, after keeping 2 cents a year earlier.
- Over the past 12 months it spent $101 million more cash than it brought in. A year earlier it had $15 million spare.
- 4% more shares than a year ago. Each share owns a bit less of the company.
- Debt is $54 million more than cash. A year ago it had $41 million more cash than debt.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $96m |
| March 2025 | $87m |
| June 2025 | $103m |
| September 2025 | $117m |
| December 2025 | $121m |
| March 2026 | $102m |
| June 2026 | $114m |
| September 2026 | $123m |
| Quarter to | Amount |
|---|---|
| December 2024 | $5m |
| March 2025 | -$7m |
| June 2025 | $11m |
| September 2025 | -$8m |
| December 2025 | -$18m |
| March 2026 | -$63m |
| June 2026 | -$18m |
| September 2026 | -$12m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 23 February 2026
- Next quarterly (estimated, 10-Q)
- 8 February 2027
Who owns it
2 long-term investors we follow own it, down from 3 last quarter. 223 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Corvex ManagementKeith Meister | $328m | 10.2% | Added |
| Royce & AssociatesChuck Royce | $8m | <0.1% | Cut |
Sold out this quarter
- Polen CapitalDan DavidowitzSold out
Largest holders overall
- Corvex Management$328mAdded
- Casdin Capital$254mAdded
- BlackRock$117mAdded
- Goldman Sachs Group$115mAdded
- ARK Investment Management$111mAdded
- William Blair Investment Management$96mAdded
- Morgan Stanley$68mAdded
- Vanguard Capital Management$60mAdded
- Citadel Advisors$59mAdded
- First Light Asset Management$54mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
8 investors own more than 5%; 2 of them are pushing for change.
- Keith A. MeisterActivistat least 17.9%0.0 pts(filed with 8 related holders)Since 20 May 2026
- Eli CasdinActivistat least 12.0%0.0 pts(filed with 5 related holders)Since 14 May 2026
- ARK Investment Management LLCPassive investorat least 6.4%+1.1 pts(filed with 1 related holder)Since 30 September 2026
- Deep Track Capital, LPPassive investorat least 6.0%(filed with 2 related holders)Since 10 November 2026
- THE GOLDMAN SACHS GROUP, INC.Passive investorat least 5.8%+1.9 pts(filed with 1 related holder)Since 30 June 2026
- BlackRock, Inc.Passive investor5.5%Since 30 June 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCPassive investor5.2%+0.9 ptsSince 30 September 2026
- Summit Partners Public Asset Management, LLCPassive investorat least 3.0%−2.1 pts(filed with 10 related holders)Since 30 June 2025
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIPassive investorSold down below 5%Since 21 February 2025
What they said
Item 4 is hereby amended and supplemented as follows: On February 19, 2025, ISMMS sold 100,000 shares of Class A Common Stock at a price of $108.5723 per share. On February 20, 2025, ISMMS sold 206,447 shares of Class A Common Stock at a price of $101.0145 per share. Each sale…
Read the filing - FMR LLCPassive investorSold down below 5%Since 30 June 2025
- Casdin Partners FO1-MSV, LPActivistSold down below 5%Since 5 May 2025
| Holder | Stake | Since | |
|---|---|---|---|
Keith A. Meister Activist | at least 17.9%0.0 pts (filed with 8 related holders) | 20 May 2026 | |
Eli Casdin Activist | at least 12.0%0.0 pts (filed with 5 related holders) | 14 May 2026 | |
ARK Investment Management LLC Passive investor | at least 6.4%+1.1 pts (filed with 1 related holder) | 30 September 2026 | |
Deep Track Capital, LP Passive investor | at least 6.0% (filed with 2 related holders) | 10 November 2026 | |
THE GOLDMAN SACHS GROUP, INC. Passive investor | at least 5.8%+1.9 pts (filed with 1 related holder) | 30 June 2026 | |
BlackRock, Inc. Passive investor | 5.5% | 30 June 2026 | |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Passive investor | 5.2%+0.9 pts | 30 September 2026 | |
Summit Partners Public Asset Management, LLC Passive investor | at least 3.0%−2.1 pts (filed with 10 related holders) | 30 June 2025 | |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Passive investor | Sold down below 5% | 21 February 2025 | What they saidItem 4 is hereby amended and supplemented as follows: On February 19, 2025, ISMMS sold 100,000 shares of Class A Common Stock at a price of $108.5723 per share. On February 20, 2025, ISMMS sold 206,447 shares of Class A Common Stock at a price of $101.0145 per share. Each sale… Read the filing |
FMR LLC Passive investor | Sold down below 5% | 30 June 2025 | |
Casdin Partners FO1-MSV, LP Activist | Sold down below 5% | 5 May 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $107m of shares on the open market. 4 sold $21m, $510,879 of it under preset trading plans.
- Feeley KevinCHIEF FINANCIAL OFFICERSold
- Date
- 16 September 2026
- Shares
- 3,728
- Price
- $97.61
- Value
- $363,892
- Stueland KatherineCHIEF EXECUTIVE OFFICER, DirectorSold
- Date
- 16 September 2026
- Shares
- 10,501
- Price
- $97.61
- Value
- $1m
- Feeley KevinCHIEF FINANCIAL OFFICERSold
- Date
- 9 September 2026
- Shares
- 1,285
- Price
- $84.22
- Value
- $108,220
- Stueland KatherineCHIEF EXECUTIVE OFFICER, DirectorSold
- Date
- 9 September 2026
- Shares
- 3,692
- Price
- $84.22
- Value
- $310,932
- Feeley KevinCHIEF FINANCIAL OFFICERSold
- Date
- 1 September 2026
- Shares
- 372
- Price
- $83.84
- Value
- $31,188
- Feeley KevinCHIEF FINANCIAL OFFICERSold
- Date
- 16 June 2026
- Shares
- 3,729
- Price
- $60.76
- Value
- $226,592
- Stueland KatherineCHIEF EXECUTIVE OFFICER, DirectorSold
- Date
- 16 June 2026
- Shares
- 10,501
- Price
- $60.76
- Value
- $638,092
- Feeley KevinCHIEF FINANCIAL OFFICERSold
- Date
- 9 June 2026
- Shares
- 1,266
- Price
- $53.77
- Value
- $68,073
- Stueland KatherineCHIEF EXECUTIVE OFFICER, DirectorSold
- Date
- 9 June 2026
- Shares
- 3,639
- Price
- $53.77
- Value
- $195,669
- Casdin EliDirectorBought
- Date
- 5 June 2026
- Shares
- 50,000
- Price
- $52.86
- Value
- $3m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 16 September 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sold | 3,728 | $97.61 | $363,892 |
| 16 September 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER, Director | Sold | 10,501 | $97.61 | $1m |
| 9 September 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sold | 1,285 | $84.22 | $108,220 |
| 9 September 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER, Director | Sold | 3,692 | $84.22 | $310,932 |
| 1 September 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sold | 372 | $83.84 | $31,188 |
| 16 June 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sold | 3,729 | $60.76 | $226,592 |
| 16 June 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER, Director | Sold | 10,501 | $60.76 | $638,092 |
| 9 June 2026 | Feeley Kevin CHIEF FINANCIAL OFFICER | Sold | 1,266 | $53.77 | $68,073 |
| 9 June 2026 | Stueland Katherine CHIEF EXECUTIVE OFFICER, Director | Sold | 3,639 | $53.77 | $195,669 |
| 5 June 2026 | Casdin Eli Director | Bought | 50,000 | $52.86 | $3m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 23 Feb 2026, plus the 10-Q filed 9 Nov 2026 and 6 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.